Broad Institute

JUNE 21, 2023

By using the tool, Clausnnitzer and others saw how a variant that reduces COBLL1 expression interferes with lipid droplets' growth within a cell. Claussnitzer's lab is now working to expand the machine-learning aspect of LipocyteProfiler, with an eye toward tracking information flow within single cells from transcription level to morphology.

Small Molecule 52

Small Molecule Cell Based Assays Medical Schools Disease 52

Molecular Design

DECEMBER 31, 2023

The effects of curcumin, EGCG (epigallocatechin gallate), genistein and resveratrol on four membrane proteins were reported in Ref9 and these effects would raise doubts about activity for any of these compounds (or their close structural analogs) that had been observed in a cell-based assay.

Drugs 96

Drugs Packaging Cell Based Assays Small Molecule 96

Drug Target Review

OCTOBER 24, 2024

Data-driven discovery As with many early-stage biotech companies, Five Alarm Bio is highly data-driven, producing vast amounts of experimental data through cell-based assays and phenotypic screening. However, managing, analysing, and leveraging this data is no easy task, especially for a small company with limited resources.

Cell Based Assays 52

Cell Based Assays Science Disease Doctors 52

Molecular Design

SEPTEMBER 18, 2024

Different assay organism or cell types: the target protein may be recombinantly expressed in different cell types (the target ID in ChEMBL is assigned based on the original source of the target), or the assays may be run using different cell types. and f > 1.0 and 27% are greater than 1.0.

Biochemical Assays 68

Biochemical Assays Drugs Biophysical Assays Cell Based Assays 68

The Pharma Data

OCTOBER 15, 2020

ASLAN003 is a highly selective and potent inhibitor of human DHODH (IC 50 = 35 nM) and has been shown to be more than 30 times more potent at inhibiting the DHODH enzyme in cell free and cell-based assays than the first generation inhibitor teriflunomide. For additional information please visit www.aslanpharma.com.

Pharmaceuticals 40

Pharmaceuticals Clinical Development Cell Based Assays Treatment 40

Molecular Design

MARCH 26, 2024

For example, we might examine the structure-activity relationship in a cell-based assay for consistency with the structure-activity relationship that we’ve observed in the enzyme inhibition assay. This information holds the potential to achieve a profound impact on the discovery of new and enhanced medicines.

Drugs 60

Drugs Pharmacokinetics Cell Based Assays Treatment 60

Agency IQ

APRIL 12, 2024

Cell-based assays , while more complex to develop and use, offer another option for characterizing product activity at a slightly higher level, allowing sponsors to measure the further downstream effects of products (e.g., morphological cell changes or alterations in protein production or expression).

Production 40

Production FDA Therapies Biochemical Assays 40

The ChEMBL-og

APRIL 16, 2024

A significant effort has been made to correctly map the drug form of the EMA data by manually inspecting different EMA sources of information, such as the Product Information (Annex I: Summary of Product Characteristics and Annex III: Labelling and Package Leaflet) and/or Assessment Report, where available. University of Dundee: T.

Clinical Trials 108

Clinical Trials FDA Cell Based Assays Compound Screening 108

Drug Target Review

JULY 6, 2023

allowing researchers to use “certain alternatives to animal testing, including cell-based assays and computer models, to obtain an exemption from the FDA to investigate the safety and effectiveness of a drug.”

Animal Testing 105

Animal Testing Drugs Clinical Trials Clinical Research 105